BioCentury
ARTICLE | Company News

AgonOx, AstraZeneca deal

November 7, 2011 8:00 AM UTC

AgonOx partnered with AstraZeneca's MedImmune LLC subsidiary to develop agonists using AgonOx's OX40 ligand ( OX40L; CD134L) technology to treat cancer. MedImmune will lead further preclinical and clinical studies. Details were not disclosed. ...